Huntington National Bank cut its position in Eli Lilly and Co. (NYSE:LLY) by 9.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 172,595 shares of the company’s stock after selling 18,773 shares during the period. Huntington National Bank’s holdings in Eli Lilly and were worth $13,592,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Iowa State Bank bought a new stake in shares of Eli Lilly and during the second quarter worth approximately $104,000. Cribstone Capital Management LLC bought a new stake in shares of Eli Lilly and during the second quarter worth approximately $117,000. Physicians Financial Services Inc. increased its stake in shares of Eli Lilly and by 11.2% in the second quarter. Physicians Financial Services Inc. now owns 1,638 shares of the company’s stock worth $129,000 after buying an additional 165 shares during the last quarter. Orrstown Financial Services Inc. increased its stake in shares of Eli Lilly and by 47.1% in the second quarter. Orrstown Financial Services Inc. now owns 1,874 shares of the company’s stock worth $148,000 after buying an additional 600 shares during the last quarter. Finally, Jolley Asset Management LLC increased its stake in shares of Eli Lilly and by 52.4% in the second quarter. Jolley Asset Management LLC now owns 2,210 shares of the company’s stock worth $174,000 after buying an additional 760 shares during the last quarter. Hedge funds and other institutional investors own 74.96% of the company’s stock.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Eli Lilly and Co. (NYSE:LLY) traded down 1.461% during midday trading on Wednesday, reaching $80.615. The company’s stock had a trading volume of 2,954,719 shares. The stock has a market capitalization of $85.27 billion, a PE ratio of 34.748 and a beta of 0.17. The firm’s 50-day moving average price is $79.63 and its 200-day moving average price is $77.69. Eli Lilly and Co. has a 52 week low of $67.88 and a 52 week high of $88.16.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 26th. The company reported $0.86 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.86. The business earned $5.40 billion during the quarter, compared to the consensus estimate of $5.14 billion. Eli Lilly and had a net margin of 11.97% and a return on equity of 23.99%. Eli Lilly and’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.90 earnings per share. On average, analysts anticipate that Eli Lilly and Co. will post $3.59 earnings per share for the current year.

A number of analysts have recently commented on the company. BMO Capital Markets restated a “buy” rating and issued a $94.00 target price on shares of Eli Lilly and in a research note on Monday, October 3rd. JPMorgan Chase & Co. upgraded Eli Lilly and from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $92.00 to $95.00 in a research note on Thursday, September 8th. Leerink Swann restated a “buy” rating and issued a $103.00 target price on shares of Eli Lilly and in a research note on Sunday. Zacks Investment Research downgraded Eli Lilly and from a “buy” rating to a “hold” rating in a research note on Wednesday, October 5th. Finally, Jefferies Group restated a “buy” rating and issued a $105.00 target price on shares of Eli Lilly and in a research note on Wednesday, September 14th. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $97.06.

In related news, major shareholder Lilly Endowment Inc sold 240,000 shares of the business’s stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $82.87, for a total transaction of $19,888,800.00. Following the completion of the sale, the insider now directly owns 126,020,570 shares of the company’s stock, valued at $10,443,324,635.90. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Maria A. Crowe sold 2,248 shares of the business’s stock in a transaction that occurred on Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total transaction of $182,919.76. Following the sale, the insider now directly owns 94,319 shares of the company’s stock, valued at $7,674,737.03. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

5 Day Chart for NYSE:LLY

Receive News & Stock Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related stocks with our FREE daily email newsletter.